154 related articles for article (PubMed ID: 32768895)
1. Nivolumab-induced seronegative encephalitis.
Cabral G; Ladeira F; Gil N
J Neuroimmunol; 2020 Oct; 347():577350. PubMed ID: 32768895
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
[TBL] [Abstract][Full Text] [Related]
3. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
4. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature.
Stuby J; Herren T; Schwegler Naumburger G; Papet C; Rudiger A
Swiss Med Wkly; 2020 Nov; 150():w20377. PubMed ID: 33232507
[TBL] [Abstract][Full Text] [Related]
6. Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment.
Samejima Y; Iuchi A; Kanai T; Noda Y; Nasu S; Tanaka A; Morishita N; Suzuki H; Okamoto N; Harada H; Ezumi A; Ueda K; Kawahara K; Hirashima T
Intern Med; 2020 Aug; 59(16):2003-2008. PubMed ID: 32448839
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange.
Chung M; Jaffer M; Verma N; Mokhtari S; Ramsakal A; Peguero E
J Neurol; 2020 Apr; 267(4):1023-1025. PubMed ID: 31832829
[TBL] [Abstract][Full Text] [Related]
8. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
Kapadia RK; Ney DE; Hannan M; Farley M; Pastula DM; Piquet AL
J Neuroimmunol; 2020 Jul; 344():577259. PubMed ID: 32416558
[TBL] [Abstract][Full Text] [Related]
9. The Occurrence of Encephalitis Due to Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Chisaki Y; Hata H; Matsumura C; Yano Y
Ther Innov Regul Sci; 2022 Mar; 56(2):323-332. PubMed ID: 35006589
[TBL] [Abstract][Full Text] [Related]
10. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
Wei D; Zhou DJ; Datta P; Taraschenko O
Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
[TBL] [Abstract][Full Text] [Related]
11. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
[TBL] [Abstract][Full Text] [Related]
12. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM
JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951
[TBL] [Abstract][Full Text] [Related]
13. A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis.
Richard K; Weslow J; Porcella SL; Nanjappa S
Cancer Control; 2017; 24(5):1073274817729069. PubMed ID: 28975824
[TBL] [Abstract][Full Text] [Related]
14. Neurotoxicities associated with immune checkpoint inhibitor therapy.
Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
[TBL] [Abstract][Full Text] [Related]
15. Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature.
Kang Y; Zhen H; Ma N; Zhao H; Cao B
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16239-16246. PubMed ID: 37676267
[TBL] [Abstract][Full Text] [Related]
16. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study.
Galmiche S; Lheure C; Kramkimel N; Franck N; Boitier F; Dupin N; Turc G; Psimaras D; Aractingi S; Guégan S
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e440-e443. PubMed ID: 31219194
[No Abstract] [Full Text] [Related]
17. Nivolumab-Induced Granuloma Annulare.
Fawaz B; Halpern A
Cutis; 2021 Jun; 107(6):E2-E4. PubMed ID: 34314320
[TBL] [Abstract][Full Text] [Related]
18. Sicca syndrome following immune checkpoint inhibition.
Mavragani CP; Moutsopoulos HM
Clin Immunol; 2020 Aug; 217():108497. PubMed ID: 32531346
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
[TBL] [Abstract][Full Text] [Related]
20. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]